Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study

NCT03006419 is registered in ClinicalTrials.gov with Coordinación de Investigación en Salud, Mexico as lead sponsor.

NCT NCT03006419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03006419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Phase
Phase 4
Overall status
Completed
Start date
December 1, 2016
Completion date
July 30, 2019
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection, kidney transplant; complications